Australia's most trusted
source of pharma news
Saturday, 18 October 2025
Posted 15 October 2025 AM
New research could expand the market for GSK's Shingrix shingles vaccine, finding that people could benefit from the blockbuster even if they were previously given the live Zostavax vaccine.
Researchers from the University of North Carolina used insurance data to study the effectiveness of Shingrix among almost 3.5 million people over 65.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.